Emma Barroso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9360522/publications.pdf

Version: 2024-02-01

31 papers	2,393 citations	236925 25 h-index	414414 32 g-index
32 all docs	32 docs citations	32 times ranked	6691 citing authors

#	Article	IF	Citations
1	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. Toxics, 2021, 9, 195.	3.7	11
2	The BACE1 product sAPPÎ² induces ER stress and inflammation and impairs insulin signaling. Metabolism: Clinical and Experimental, 2018, 85, 59-75.	3.4	26
3	Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Trends in Endocrinology and Metabolism, 2018, 29, 178-190.	7.1	365
4	Hepatic regulation of VLDL receptor by PPARÎ²/Î´ and FGF21 modulates non-alcoholic fatty liver disease. Molecular Metabolism, 2018, 8, 117-131.	6.5	77
5	PPARÎ²/Î´: A Key Therapeutic Target in Metabolic Disorders. International Journal of Molecular Sciences, 2018, 19, 913.	4.1	66
6	Small heterodimer partner (SHP) contributes to insulin resistance in cardiomyocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 541-551.	2.4	10
7	VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells. Diabetologia, 2017, 60, 2262-2273.	6.3	29
8	Heme-Regulated eIF2Î± Kinase Modulates Hepatic FGF21 and Is Activated by PPARÎ²/Î´ Deficiency. Diabetes, 2016, 65, 3185-3199.	0.6	31
9	PPARÎ²/Î´ and lipid metabolism in the heart. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1569-1578.	2.4	39
10	Carnitine palmitoyltransferase-1 up-regulation by PPAR-Î²/Î´ prevents lipid-induced endothelial dysfunction. Clinical Science, 2015, 129, 823-837.	4.3	42
11	High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1687-1699.	3.8	134
12	Targeting endoplasmic reticulum stress in insulin resistance. Trends in Endocrinology and Metabolism, 2015, 26, 438-448.	7.1	172
13	miR-146a targets c-Fos expression in human cardiac cells. DMM Disease Models and Mechanisms, 2015, 8, 1081-91.	2.4	35
14	PPARÎ²/Î´ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1049-1058.	3.8	21
15	PPARÎ²/Î´ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia, 2014, 57, 2126-2135.	6.3	83
16	PPARÎ²/Î´ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. International Journal of Cardiology, 2014, 174, 110-118.	1.7	58
17	Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1556-1566.	3.8	161
18	Oleate prevents saturated-fatty-acid-induced ER stress, inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia, 2013, 56, 1372-1382.	6.3	173

#	Article	IF	Citations
19	Resveratrol induces nuclear factor-Î¹B activity in human cardiac cells. International Journal of Cardiology, 2013, 167, 2507-2516.	1.7	28
20	Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARÎ²/Î´-null mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1241-1248.	3.8	37
21	An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. International Journal of Cardiology, 2013, 168, 3160-3172.	1.7	238
22	TNF-Î± inhibits PPARÎ²/Î´ activity and SIRT1 expression through NF-Î¹B in human adipocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 1177-1185.	2.4	45
23	Metabolic Alterations and Increased Liver mTOR Expression Precede the Development of Autoimmune Disease in a Murine Model of Lupus Erythematosus. PLoS ONE, 2012, 7, e51118.	2.5	26
24	Targeting PPARÎ²/Î´ for the treatment of type 2 diabetes mellitus. Expert Opinion on Therapeutic Targets, 2012, 16, 209-223.	3.4	36
25	The peroxisome proliferator-activated receptor (PPAR) Î²/Î´ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia, 2012, 55, 743-751.	6.3	59
26	The PPARÎ²/Î´ Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1Î±-Lipin 1-PPARÎ± Pathway Leading to Increased Fatty Acid Oxidation. Endocrinology, 2011, 152, 1848-1859.	2.8	136
27	The peroxisome proliferator-activated receptor Î²/Î´ (PPARÎ²/Î´) agonist GW501516 prevents TNF-Î±-induced NF-Î¹B activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. Biochemical Pharmacology, 2011, 81, 534-543.	4.4	61
28	Activation of Peroxisome Proliferator-Activated Receptor-Î´ by GW501516 Prevents Fatty Acid-Induced Nuclear Factor-Î¹B Activation and Insulin Resistance in Skeletal Muscle Cells. Endocrinology, 2010, 151, 1560-1569.	2.8	80
29	The Role of Peroxisome Proliferator-Activated Receptor Î²/Î´ on the Inflammatory Basis of Metabolic Disease. PPAR Research, 2010, 2010, 1-11.	2.4	22
30	Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology, 2009, 49, 106-115.	7.3	58
31	Peroxisome Proliferator-Activated Receptor Â Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1326-1336.	3.6	26